Massimo Breccia

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.

M. Breccia, G. Alimena, Massimo Breccia, 2010, Leukemia research.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Paola Fazi, Marco Vignetti, Giuseppe Avvisati, 2013, The New England journal of medicine.

Flt3L induces the ex‐vivo amplification of umbilical cord blood committed progenitors and early stem cells in short‐term cultures

T. Di Pucchio, F. Mandelli, A. Tafuri, 1999, British journal of haematology.

Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC)

Salvatore Giacomo Morano, Robin Foà, Angelo Fama, 2015, Supportive Care in Cancer.